Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Neural Regulation01:37

Neural Regulation

39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Insights into the Antimicrobial Properties of Phyllanthus emblica L.: A Comprehensive Review of Wonder Berry.

Chemistry & biodiversity·2024
Same author

Safeguarding Neuronal Integrity: Unveiling Possible Role of NFκB in the Neuroprotective Efficacy of Andrographolide Contrary to Aluminium Chloride-induced Neurotoxicity and Associated Spatial Memory Impairments in Rats.

Central nervous system agents in medicinal chemistry·2024
Same author

Medicinal Plants in the Treatment of Myocardial Infarction Disease: A Systematic Review.

Current cardiology reviews·2024
Same author

A Comprehensive Review on Therapeutic Potential of a Natural Anthraquinone Derivative Emodin in Brain-related Disorders.

Current drug targets·2023
Same author

Enhanced self-propulsion of a sphere-dimer in viscoelastic fluid.

Soft matter·2019

Related Experiment Video

Updated: Jun 4, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.4K

Lead Phytomolecules for Treating Parkinson's Disease.

Krishn Kumar Agrawal1,2, Chandra Veer2, Yogesh Murti2

  • 1Dr. A.P.J. Abdul Kalam Technical University, Lucknow, 226031, India.

Central Nervous System Agents in Medicinal Chemistry
|December 19, 2024
PubMed
Summary

Parkinson's disease involves neuron loss and motor deficits. Phytomolecules offer neuroprotection by reducing oxidative stress and apoptosis, paving the way for novel Parkinson's disease therapies.

Keywords:
Parkinson's diseasedopaminergic neuronsferroptosisneuroinflammation.nigrostriatal pathwayphytomolecules

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.9K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.3K

Related Experiment Videos

Last Updated: Jun 4, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.4K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.9K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.3K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Parkinson's disease (PD) affects 1% of individuals over 65, characterized by dopaminergic neuron loss in the nigrostriatal pathway.
  • Mutations in Parkin and PINK1 genes impair mitophagy and mitochondrial function, contributing to PD pathogenesis.
  • PD is associated with motor impairments (bradykinesia, rigidity, tremor) and non-motor symptoms, influenced by α-synuclein aggregation and impaired proteolytic defense.

Purpose of the Study:

  • To investigate the mechanisms underlying Parkinson's disease.
  • To explore the neuroprotective potential of phytomolecules in Parkinson's disease.
  • To identify novel therapeutic strategies for Parkinson's disease.

Main Methods:

  • Review of existing literature on Parkinson's disease mechanisms, including genetic factors, oxidative stress, ferroptosis, mitochondrial failure, and neuroinflammation.
  • Analysis of signaling pathways implicated in PD, such as α-synuclein aggregation.
  • Examination of the neuroprotective effects of specific phytomolecules (curcumin, β-amyrin, berberine, capsaicin, gentisic acid).

Main Results:

  • Parkinson's disease pathogenesis involves complex interactions including oxidative stress, ferroptosis, mitochondrial dysfunction, and neuroinflammation.
  • Phytomolecules demonstrate neuroprotective properties by reducing reactive oxygen species (ROS) levels.
  • These compounds mitigate α-synuclein toxicity and protect cells from apoptosis, suggesting therapeutic potential.

Conclusions:

  • Understanding the intricate mechanisms of Parkinson's disease is crucial for developing effective treatments.
  • Phytomolecules represent a promising avenue for Parkinson's disease therapy due to their multifaceted neuroprotective actions.
  • Further research into these mechanisms and phytomolecules can lead to the development of improved therapeutic interventions for PD.